RESUMO
BACKGROUND: In high-resource settings, the survival of children with immunocompromise (IC) has increased and immunosuppressive therapies are increasingly being used. This study aimed to determine the clinical characteristics, performance of diagnostic tools, and outcome of IC children with tuberculosis (TB) in Europe. METHODS: Multicenter, matched case-control study within the Pediatric Tuberculosis Network European Trials Group, capturing TB cases <18 years diagnosed 2000-2020. RESULTS: A total of 417 TB cases were included, comprising 139 children who are IC (human immunodeficiency virus, inborn errors of immunity, drug-induced immunosuppression, and other immunocompromising conditions) and 278 non-IC children as controls. Nonrespiratory TB was more frequent among cases than controls (32.4% vs 21.2%; P = .013). Patients with IC had an increased likelihood of presenting with severe disease (57.6% vs 38.5%; P < .001; odds ratio [95% confidence interval], 2.073 [1.37-3.13]). Children with IC had higher rates of false-negative tuberculin skin test (31.9% vs 6.0%; P < .001) and QuantiFERON-TB Gold assay (30.0% vs 7.3%; P < .001) results at diagnosis. Overall, the microbiological confirmation rate was similar in IC and non-IC cases (58.3% vs 49.3%; P = .083). Although the mortality in children with IC was <1%, the rate of long-term sequelae was significantly higher than in non-IC cases (14.8% vs 6.1%; P = .004). CONCLUSIONS: Children with IC and TB in Europe have increased rates of nonrespiratory TB, severe disease, and long-term sequelae. Immune-based TB tests have poor sensitivity in those children. Future research should focus on developing improved immunological TB tests that perform better in patients with IC, and determining the reasons for the increased risk of long-term sequelae, with the aim to design preventive management strategies.
Assuntos
Hospedeiro Imunocomprometido , Tuberculose , Humanos , Estudos de Casos e Controles , Criança , Masculino , Feminino , Adolescente , Europa (Continente)/epidemiologia , Tuberculose/epidemiologia , Tuberculose/diagnóstico , Pré-Escolar , Lactente , Teste Tuberculínico , Antituberculosos/uso terapêuticoRESUMO
RATIONALE: In 2016, a new interferon-gamma release assay (IGRA) was introduced, QuantiFERON-TB Gold Plus (QFT-Plus), claimed to have improved sensitivity in active tuberculosis (TB). OBJECTIVES: This study aimed to determine the performance of QFT-Plus, compared with previous generation IGRAs and the tuberculin skin test (TST), in children with TB in Europe. METHODS: Multicentre, ambispective cohort study within the Paediatric Tuberculosis Network European Trials Group (ptbnet), a dedicated paediatric TB research network comprising >300 members, capturing TB cases <18 years-of-age diagnosed between January 2009 and December 2019. MEASUREMENTS AND MAIN RESULTS: 1001 TB cases from 16 countries were included (mean age (IQR) 5.6 (2.4-12.1) years). QFT-Plus was performed in 358, QFT Gold in-Tube (QFT-GIT) in 600, T-SPOT.TB in 58 and TST in 636 cases. The overall test sensitivities were: QFT-Plus 83.8% (95% CI 80.2% to 87.8%), QFT-GIT 85.5% (95% CI 82.7% to 88.3%), T-SPOT.TB 77.6% (95% CI 66.9% to 88.3%) and TST (cut-off ≥10 mm) 83.3% (95% CI 83.3% to 86.2%). There was a trend for tests to have lower sensitivity in patients with miliary and/or central nervous system (CNS) TB (73.1%, 70.9%, 63.6% and 43.5%, respectively), and in immunocompromised patients (75.0%, 59.6%, 45.5% and 59.1%, respectively). CONCLUSIONS: The results indicate that the latest generation IGRA assay, QFT-Plus, does not perform better than previous generation IGRAs or the TST in children with TB disease. Overall, tests performed worse in CNS and miliary TB, and in immunocompromised children. None of the tests evaluated had sufficiently high sensitivity to be used as a rule-out test in children with suspected TB.
Assuntos
Tuberculose Latente , Tuberculose , Humanos , Criança , Pré-Escolar , Estudos de Coortes , Tuberculose/diagnóstico , Testes de Liberação de Interferon-gama/métodos , Teste Tuberculínico/métodos , Europa (Continente) , Tuberculose Latente/diagnósticoRESUMO
BACKGROUND: Adults are being vaccinated against SARS-CoV-2 worldwide, but the longitudinal protection of these vaccines is uncertain, given the ongoing appearance of SARS-CoV-2 variants. Children remain largely unvaccinated and are susceptible to infection, with studies reporting that they actively transmit the virus even when asymptomatic, thus affecting the community. METHODS: We investigated if saliva is an effective sample for detecting SARS-CoV-2 RNA and antibodies in children, and associated viral RNA levels to infectivity. For that, we used a saliva-based SARS-CoV-2 RT-qPCR test, preceded or not by RNA extraction, in 85 children aged 10 years and under, admitted to the hospital regardless of COVID-19 symptomatology. Amongst these, 29 (63.0%) presented at least one COVID-19 symptom, 46 (54.1%) were positive for SARS-CoV-2 infection, 28 (32.9%) were under the age of 1, and the mean (SD) age was 3.8 (3.4) years. Saliva samples were collected up to 48 h after a nasopharyngeal swab-RT-qPCR test. RESULTS: In children aged 10 years and under, the sensitivity, specificity, and accuracy of saliva-RT-qPCR tests compared to NP swab-RT-qPCR were, respectively, 84.8% (71.8%-92.4%), 100% (91.0%-100%), and 91.8% (84.0%-96.6%) with RNA extraction, and 81.8% (68.0%-90.5%), 100% (91.0%-100%), and 90.4% (82.1%-95.0%) without RNA extraction. Rescue of infectious particles from saliva was limited to CT values below 26. In addition, we found significant IgM positive responses to SARS-CoV-2 in children positive for SARS-CoV-2 by NP swab and negative by saliva compared to other groups, indicating late infection onset (>7-10 days). CONCLUSIONS: Saliva is a suitable sample type for diagnosing children aged 10 years and under, including infants aged <1 year, even bypassing RNA extraction methods. Importantly, the detected viral RNA levels were significantly above the infectivity threshold in several samples. Further investigation is required to correlate SARS-CoV-2 RNA levels to viral transmission.
Assuntos
COVID-19 , SARS-CoV-2 , Adulto , COVID-19/diagnóstico , Teste para COVID-19 , Criança , Técnicas de Laboratório Clínico/métodos , Humanos , Técnicas de Diagnóstico Molecular , Nasofaringe , RNA Viral/análise , RNA Viral/genética , SARS-CoV-2/genética , Saliva/química , Manejo de Espécimes/métodosRESUMO
INTRODUCTION: The diagnosis of tuberculosis in children is a challenge namely because extrapulmonary tuberculosis and severe disease are more frequent in this age group. The aim of this study was to evaluate and reflect about severe tuberculosis in pediatric age, in a metropolitan area of Lisbon. MATERIAL AND METHODS: Descriptive study about patients under 18 years of age admitted with tuberculosis disease in a tertiary pediatric hospital, from 2008 to 2019 (12 years). RESULTS: We report 145 patients, average of 12 cases/year, with an increase in the last three years. Median age of 12.9 years, 42.8% born in Portuguese-speaking African countries and 20% had a chronic disease. The diagnosis was pulmonary tuberculosis in 52.4% (n = 76) and extrapulmonary tuberculosis in 47.6%: lymphatic (n = 26), skeletal (n = 15), miliary (n = 8), meningeal (n = 7), peritoneal/ intestinal (n = 6), pleural (n = 4), renal (n = 1), cutaneous (n = 1), thoracic wall (n = 1) and salivary glands (n = 1). The tuberculin test was positive in 78/99 (78.8%) and Interferon Gamma Release Assay in 61/90 (67.8%). In 20.7% (n = 30) acid-fast bacilli were identified in gastric aspirate/sputum and the agent was identified in 59.3% (n = 86). Tuberculosis was resistant in 11% (n = 16). Patients with extrapulmonary tuberculosis were younger (p = 0.006) and had more prolonged therapy (p < 0.001). Therapy-related complications occurred in 11% (n = 16). One patient died (with terminal cancer). CONCLUSION: This study highlights the need for screening of tuberculosis in children from endemic countries, patients with immunosuppression and chronic disease.
Introdução: Em Pediatria, o diagnóstico de tuberculose constitui um desafio, pois a doença pode frequentemente manifestar-se através de formas graves e extrapulmonares. O objetivo deste estudo foi avaliar e refletir sobre a tuberculose grave com necessidade de internamento, em idade pediátrica, numa área metropolitana de Lisboa.Material e Métodos: Estudo descritivo de doentes com idade inferior a 18 anos, internados com o diagnóstico de tuberculose num hospital pediátrico terciário, de 2008 a 2019 (12 anos).Resultados: Identificados 145 doentes, numa média de 12 casos por ano, e um aumento do número de casos nos últimos três anos. A mediana de idades dos doentes era de 12,9 anos, 42,8% nascidos em países africanos de língua oficial portuguesa e 20% tinham doença crónica. Diagnosticou-se tuberculose pulmonar em 52,4% (n = 76) e tuberculose extrapulmonar em 47,6%: ganglionar (n = 26), óssea (n = 15), miliar (n = 8), meníngea (n = 7), peritoneal/intestinal (n = 6), pleural (n = 4), renal (n = 1), cutânea (n = 1), da parede torácica (n = 1) e glândulas salivares (n = 1). A prova tuberculínica foi positiva em 78/99 (78,8%) e o Interferon Gamma Release Assay em 61/90 (67,8%). Em 20,7% (n = 30) identificaram-se bacilos ácido-álcool resistentes no exame direto do suco gástrico/expetoração e o agente foi identificado em 59,3% (n = 86). A tuberculose resistente ocorreu em 11% (n = 16). Os doentes com tuberculose extrapulmonar eram mais jovens (p = 0,006) e fizeram tratamentos mais prolongados (p < 0,001). Ocorreram complicações da terapêutica em 11% (n = 16). Registou-se um óbito numa doente com neoplasia avançada.Conclusão: Este estudo alerta para a necessidade do rastreio da infeção em crianças de países endémicos, imunossuprimidos e com doença crónica.
RESUMO
When therapy with hepatotoxic drugs is being considered, all other possible contributing agents of liver damage should be held to account. While not generally considered a risk factor, we present 2 cases in which ketogenic diet (KD) may have played a role in liver injury due to antituberculosis drugs. Ketogenic diet has been linked to liver injury, and while its pathophysiology remains obscure, carnitine depletion could play a role, as it is a mechanism of liver damage common to KD and antituberculosis drug regimens.
RESUMO
INTRODUCTION/OBJECTIVES: By May 2020, SARS-CoV-2 had caused more than 400 000 deaths worldwide. Initially, hydroxychloroquine was a treatment option for COVID-19. More recent studies have questioned its safety and efficacy and, until stronger evidence is available, it was suspended from therapy protocols. We describe our experience treating COVID-19 Portuguese pediatric patients with hydroxychloroquine, having applied a protocol for monitoring cardiac toxicity. METHODS: An observational retrospective study of COVID-19 pediatric patients, admitted from March to April 2020 and treated with hydroxychloroquine. Cardiotoxicity was assessed using ECG recordings and corrected QT-time (QTc). Patients were classified into risk-groups depending on QTc value: normal, slightly elevated or severely elevated (>500 ms). RESULTS: Total of 14 patients, with a median age of 10 years [four months; 17 years], treated with hydroxychloroquine for a median of five days. Hydroxychloroquine was used in monotherapy in six patients (mainly mild disease with comorbidities), and in association with lopinavir/ritonavir (3) and azithromycin (5) in moderate to severe disease. Other QT-prolonging therapies were used in five patients: oseltamivir (3), omeprazole (1), morphine (1) and ketamine (1). At 48 hours of treatment, two patients temporarily suspended hydroxychloroquine due to QTc prolongation (>500 ms). All patients completed the whole treatment. No other side effects or deaths occurred. CONCLUSION: Clinical trials are evolving to define hydroxychloroquine effectivity and safety. Our considerable pediatric population supports the need for cardiotoxicity monitoring during therapy but suggest its use seems to be safe in COVID-19 pediatric patients, even in association with other QT-prolonging therapies.
INTRODUÇÃO/OBJETIVO: A hidroxicloroquina foi inicialmente uma das opções terapêuticas na Covid-19. Descreve-se o tratamento com hidroxicloroquina em doentes Covid-19 pediátricos, tendo aplicado um protocolo de monitoração cardíaca pelo seu potencial arritmogénico. MÉTODOS: Estudo observacional retrospetivo de doentes pediátricos com Covid-19, internados de março a abril 2020, medicados com hidroxicloroquina. A monitoração cardíaca foi realizada por eletrocardiogramas regulares e cálculo do intervalo QT corrigido durante o tratamento. Os doentes foram classificados consoante o valor de QTc: normal, moderadamente aumentado ou muito aumentado (>500 msg). RESULTADOS: Total de 14 doentes, com mediana de 10 anos [4 meses; 17 anos], medicados com HCQ durante uma mediana de 5 dias em doentes com pneumonia ou comorbilidades. A monoterapia foi realizada em 6 doentes, 4 com fatores de risco, e em associação com lopinavir/ritonavir (3) e azitromicina (5) na doença grave e moderada. Foram ainda usados fármacos capazes de prolongar o intervalo QT: oseltamivir (3), omeprazol (1), cetamina e morfina (1) em 5 doentes. Após 48 horas de terapêutica, dois doentes apresentaram intervalo QTc muito aumentado, condicionando suspensão temporária do fármaco. Todos os doentes concluíram o tratamento sem outros efeitos adversos. CONCLUSÃO: A HCQ permanece em ensaios clínicos para avaliação da sua efetividade e segurança. A nossa amostra considerável em doentes pediátricos apoia a necessidade de monitoração de toxicidade cardíaca, mas sugere na população estudada, mesmo na associação com outros fármacos que prolongam o intervalo QT, a segurança de sua utilização.
Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Terapia Antirretroviral de Alta Atividade/efeitos adversos , Síndrome Inflamatória da Reconstituição Imune/etiologia , Microangiopatias Trombóticas/complicações , Antibacterianos/uso terapêutico , Diagnóstico Diferencial , Evolução Fatal , Humanos , Síndrome Inflamatória da Reconstituição Imune/tratamento farmacológico , Imunoglobulinas/uso terapêutico , Lactente , Linfo-Histiocitose Hemofagocítica/complicações , Linfo-Histiocitose Hemofagocítica/tratamento farmacológico , Masculino , Metilprednisolona/uso terapêutico , Microangiopatias Trombóticas/tratamento farmacológicoRESUMO
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious dermatologic diseases with many potential multisystem complications. We describe the case of an 8-year-old girl who developed severe SJS/TEN overlap syndrome (25% of her body surface area was affected) complicated by pancreatitis and bronchiolitis obliterans. These rare complications emphasize the need for careful, intensive monitoring of possible complications and an interdisciplinary team approach to provide optimal treatment and follow-up.